How will #RealWorldEvidence studies affect clinical research and regulatory decision-making in the years to come? From leveraging the patient voice to complementing randomized controlled trials, RWE studies are no longer only supporting post-approval surveillance of drug safety, but are increasingly taking on a greater role in pre-authorization Check out Harpreet Singh, MD's recent article in Nature Medicine for the full article: https://lnkd.in/ehxP5xHX
Nature Medicine recently featured perspective from Harpreet Singh, MD, Precision’s CMO, in a news article on how real-world evidence is reshaping clinical research and regulatory decision-making. Harpreet comments on the FDA’s approval of eflornithine using an external control and PRAGMATICA-LUNG as an example of a faster, leaner, more inclusive cancer trial. The central takeaway is that real-world evidence will not replace randomized trials, and it can help answer important questions that traditional trials are not always built to address. Read the article here: https://lnkd.in/eez7vRuf Note: Article is behind a paywall. #RWE #ClinicalTrials #Oncology
